Immutep (ASX:IMM) has announced the appointment of four new members to its Clinical Advisory Board (CAB).
The company is developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune diseases.
Immutep's Dr Frederic Triebel said, “We are privileged to have a group of leading oncologists on our Clinical Advisory Board and are pleased to welcome several new members.
"The CAB’s experience in the development of ground-breaking new cancer therapies will be invaluable as we look to advance efti into important late-stage development programs. In the coming months, we expect the CAB will particularly focus on our programs addressing metastatic breast and non-small cell lung carcinomas.”
The new appointments are Scott Antonia, MD, Ph.D, who currently serves as the director of the Duke Cancer Institute Center for Cancer Immunotherapy and is a member of the Thoracic Oncology disease group as Professor of Medical Oncology.
Leisha A Emens, MD, Ph.D is a Professor of Medicine at the UPMC Hillman Cancer Center, Martin Forster, MD. Ph.D is an associate professor at University College London and consultant medical oncologist at University College Hospital, and Hans Wildiers, MD, Ph.D is a dedicated breast cancer researcher and medical oncologist who has been a staff member at the Department of Medical Oncology at the University Hospital Leuven in Belgium since 2004.